Roche Holding AG’s Genentech unit achieved superior phase III results with its KRAS G12C inhibitor divarasib over approved ...

What does med tech in 2026 look like? Uncertainty remains. Global investors are confident about exit opportunities in the year ahead. But financing will be targeted. For the med-tech companies, ...

Nearly 60% of venture capital financing rounds in the first half (H1) of 2026 were over $100 million, with the volume of ...

FAM3D is a protein mainly expressed in the gastrointestinal tract, but also detectable in vascular endothelial cells. It is known to worsen intestinal inflammation by recruiting neutrophils, but its ...

Focal adhesion kinase (FAK), a key mediator of cell adhesion and migration, is frequently upregulated in glioblastoma (GBM), where its activity has been associated with increased tumor invasiveness ...

Merck Sharp & Dohme LLC (MSD) has synthesized new benzimidazole derivatives acting as NLRP3 inflammasome inhibitors. As such, they are potentially useful for the treatment of atherosclerosis, ...

Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm ...

Total med-tech financing through the first half of 2026 reached $12.28 billion, landing between 2024’s $13.94 billion and ...

Ltd. was the third Chinese biotech company to debut in Hong Kong this month, with June IPO proceeds from Alebund, Longbio ...

Ipsen SA announced its second acquisition of the week, saying it will pay €700 million (US$797 million) for Memo Therapeutics ...

To Ivan Oransky, China’s paper-mill problem is best understood as an incentives story. “This is literally organized crime,” the Retraction Watch co-founder told BioWorld. “Follow the money. When there ...

Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, ...